CN113543783A - 激酶抑制剂化合物和组合物及使用方法 - Google Patents
激酶抑制剂化合物和组合物及使用方法 Download PDFInfo
- Publication number
- CN113543783A CN113543783A CN201980093323.0A CN201980093323A CN113543783A CN 113543783 A CN113543783 A CN 113543783A CN 201980093323 A CN201980093323 A CN 201980093323A CN 113543783 A CN113543783 A CN 113543783A
- Authority
- CN
- China
- Prior art keywords
- compound
- nmr
- tof
- esi
- hrms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862786991P | 2018-12-31 | 2018-12-31 | |
| US62/786,991 | 2018-12-31 | ||
| PCT/US2019/069059 WO2020142486A1 (en) | 2018-12-31 | 2019-12-31 | Kinase inhibitor compounds and compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113543783A true CN113543783A (zh) | 2021-10-22 |
Family
ID=71407427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980093323.0A Pending CN113543783A (zh) | 2018-12-31 | 2019-12-31 | 激酶抑制剂化合物和组合物及使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220064146A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3906028A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022515650A (cg-RX-API-DMAC10.html) |
| CN (1) | CN113543783A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019418800A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3124353A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020142486A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| JPWO2023008470A1 (cg-RX-API-DMAC10.html) * | 2021-07-28 | 2023-02-02 | ||
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011133888A1 (en) * | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyrimidines, compositions thereof, and methods for their use |
| WO2011133882A1 (en) * | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridazines, compositions thereof, and methods of their use |
| CN102712601A (zh) * | 2009-11-12 | 2012-10-03 | 赛尔维他股份公司 | 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂 |
| WO2015058031A1 (en) * | 2013-10-17 | 2015-04-23 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| WO2017040993A1 (en) * | 2015-09-03 | 2017-03-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1a and uses thereof |
| WO2017085198A1 (en) * | 2015-11-20 | 2017-05-26 | Actelion Pharmaceuticals Ltd | N-substituted indole derivatives as pge2 receptor modulators |
| WO2018098561A1 (en) * | 2016-12-01 | 2018-06-07 | Aptose Biosciences Inc. | Fused pyrimidine compounds as brd4 and jak2 dual inhibitors and methods for use thereof |
| WO2018210994A1 (en) * | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200301123A (en) * | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| US20130102627A1 (en) * | 2010-04-09 | 2013-04-25 | The Brigham And Women's Hospital, Inc. | Acridines As Inhibitors Of Haspin And DYRK Kinases |
| KR102006749B1 (ko) * | 2011-08-19 | 2019-08-02 | 디악쏘니 | Dyrk1 억제제 및 이의 용도 |
| SG11201406584TA (en) * | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
-
2019
- 2019-12-31 CA CA3124353A patent/CA3124353A1/en active Pending
- 2019-12-31 CN CN201980093323.0A patent/CN113543783A/zh active Pending
- 2019-12-31 WO PCT/US2019/069059 patent/WO2020142486A1/en not_active Ceased
- 2019-12-31 JP JP2021538205A patent/JP2022515650A/ja active Pending
- 2019-12-31 EP EP19907897.3A patent/EP3906028A4/en active Pending
- 2019-12-31 US US17/418,607 patent/US20220064146A1/en active Pending
- 2019-12-31 AU AU2019418800A patent/AU2019418800A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102712601A (zh) * | 2009-11-12 | 2012-10-03 | 赛尔维他股份公司 | 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂 |
| WO2011133888A1 (en) * | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyrimidines, compositions thereof, and methods for their use |
| WO2011133882A1 (en) * | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridazines, compositions thereof, and methods of their use |
| WO2015058031A1 (en) * | 2013-10-17 | 2015-04-23 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| WO2017040993A1 (en) * | 2015-09-03 | 2017-03-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1a and uses thereof |
| WO2017085198A1 (en) * | 2015-11-20 | 2017-05-26 | Actelion Pharmaceuticals Ltd | N-substituted indole derivatives as pge2 receptor modulators |
| WO2018098561A1 (en) * | 2016-12-01 | 2018-06-07 | Aptose Biosciences Inc. | Fused pyrimidine compounds as brd4 and jak2 dual inhibitors and methods for use thereof |
| WO2018210994A1 (en) * | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
Non-Patent Citations (1)
| Title |
|---|
| THOMAS C. COOMBS 等: "Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe ML315", BIOORG MED CHEM LETT., vol. 23, no. 12, pages 3654 - 3661, XP028543373, DOI: 10.1016/j.bmcl.2013.02.096 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3124353A1 (en) | 2020-07-09 |
| AU2019418800A1 (en) | 2021-07-01 |
| WO2020142486A1 (en) | 2020-07-09 |
| EP3906028A4 (en) | 2022-10-12 |
| JP2022515650A (ja) | 2022-02-21 |
| US20220064146A1 (en) | 2022-03-03 |
| EP3906028A1 (en) | 2021-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12421232B2 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| US20230234935A1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| US20220064146A1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| US7541367B2 (en) | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | |
| JP6993985B2 (ja) | イソキノリン-3イル-カルボキサミドならびにその調製および使用の方法 | |
| US8354526B2 (en) | Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors | |
| EP3906233B1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| US20090143361A1 (en) | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | |
| KR20120140643A (ko) | 키나아제 억제제 | |
| US20250215013A1 (en) | Substituted tricyclic compounds as parp inhibitors and the use thereof | |
| US11547712B2 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| HK40063467A (en) | Kinase inhibitor compounds and compositions and methods of use | |
| HK40062251A (en) | Kinase inhibitor compounds and compositions and methods of use | |
| EP4396191B1 (en) | Compounds useful in modulation of ahr signalling | |
| HK1177208B (en) | Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40063467 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211022 |